Broad Institute of MIT and Harvard, Medical and Population Genetics Program, Cambridge, MA 02141, USA.
BMC Genomics. 2012 Aug 5;13:375. doi: 10.1186/1471-2164-13-375.
Pacific Biosciences technology provides a fundamentally new data type that provides the potential to overcome some limitations of current next generation sequencing platforms by providing significantly longer reads, single molecule sequencing, low composition bias and an error profile that is orthogonal to other platforms. With these potential advantages in mind, we here evaluate the utility of the Pacific Biosciences RS platform for human medical amplicon resequencing projects.
We evaluated the Pacific Biosciences technology for SNP discovery in medical resequencing projects using the Genome Analysis Toolkit, observing high sensitivity and specificity for calling differences in amplicons containing known true or false SNPs. We assessed data quality: most errors were indels (14%) with few apparent miscalls (1%). In this work, we define a custom data processing pipeline for Pacific Biosciences data for human data analysis.
Critically, the error properties were largely free of the context-specific effects that affect other sequencing technologies. These data show excellent utility for follow-up validation and extension studies in human data and medical genetics projects, but can be extended to other organisms with a reference genome.
Pacific Biosciences 技术提供了一种全新的数据类型,通过提供更长的读长、单分子测序、低组成偏差和与其他平台正交的错误模式,有可能克服当前下一代测序平台的一些限制。考虑到这些潜在的优势,我们在这里评估 Pacific Biosciences RS 平台在人类医学扩增子重测序项目中的实用性。
我们使用基因组分析工具包评估了 Pacific Biosciences 技术在医学重测序项目中的 SNP 发现能力,观察到在包含已知真或假 SNP 的扩增子中调用差异的高灵敏度和特异性。我们评估了数据质量:大多数错误是插入缺失(14%),很少有明显的误报(1%)。在这项工作中,我们为人类数据分析定义了一个 Pacific Biosciences 数据的自定义数据处理管道。
至关重要的是,错误特性在很大程度上不受影响其他测序技术的特定于上下文的影响。这些数据在人类数据和医学遗传学项目的后续验证和扩展研究中具有极好的应用价值,但可以扩展到具有参考基因组的其他生物体。